The University of Southampton
University of Southampton Institutional Repository

CD27 agonist antibodies mediate clinical responses through intratumoral stimulation in B-cell malignancies: multicenter RiVa trial

CD27 agonist antibodies mediate clinical responses through intratumoral stimulation in B-cell malignancies: multicenter RiVa trial
CD27 agonist antibodies mediate clinical responses through intratumoral stimulation in B-cell malignancies: multicenter RiVa trial
Purpose: varlilumab is a CD27 agonist antibody, delivering a T-cell costimulation. Preclinical studies show that agonistic CD27 antibodies can activate intratumoral T-cells to release chemokines and cytokines to augment macrophage-dependent tumor killing induced by CD20 antibodies, i.e. rituximab, in B-cell lymphoma. This clinical trial evaluated the safety and efficacy of rituximab and varlilumab in patients with previously treated B-cell non-Hodgkin lymphoma (B-NHL).

Patient and methods: this multicenter phase IIa trial recruited patients with relapsed or refractory CD20+ B-NHL. Patients were randomized to Arm A or B. All received rituximab on Day 1 of Cycles1-6, and varlilumab on Day 2 (Arm A) or Day 8 (Arm B) of Cycle 1, and Day 2 of Cycles 3 and 5. Tumor biopsies were collecting pre-treatment and on-treatment (after varlilumab in Arm A and before varlilumab in Arm B). The primary objective was to assess safety and anti-tumor activity.

Results: twenty-seven participants were evaluable, with modest overall response and disease control rates of 15.4% (4/27) and 38.8% (8/27), respectively. Intratumoral bulk RNA sequencing analysis demonstrated that adding varlilumab to rituximab enhanced CD4+ T-cell infiltration and increased T- and innate-cell signatures; inflamed tumor signatures were observed pre-treatment in responders. Single-cell analysis further showed that higher levels of CD27-expressing T and NK cells, along with activated γδ T-cell signatures, were associated with response, whereas CD27-expressing B cells correlated with non-response.

Conclusions: rituximab and varlilumab show modest activity. However, CD27 agonist antibodies may elicit meaningful anti-tumor responses when tumors express sufficient intratumoral targets and exhibit existing immune priming.
1078-0432
Buermann, Lara E.
953ffde8-80f4-4bc7-b36b-0502d1e3ff82
Stanton, Louise
8b827763-d839-4b4b-bbf2-358a84110294
Rose-Zerilli, Matthew J.J.
08b3afa4-dbc2-4c0d-a852-2a9f33431199
Thorne, Kerensa
21a60886-12d9-4ace-b9cd-cf0f64aca53d
Coleman, Adam
49cf504d-6f2b-422b-9c3a-17eb5d5d6a85
Turaj, Anna H.
fbbc48ea-28cf-4db7-ae4a-c16ce7b3857a
Caddy, Joshua
c9f48059-2d70-45e4-a80a-978bf74fac34
Wignall, Christopher
0fd9e11b-8f96-467f-810c-041bbfca40bc
Keyworth, Nicole
3040ee74-31cf-4cbd-91ef-3223367f7253
Konn, Zoe
525b4648-7c88-488a-aefa-0018ac485eb4
McKay, Pamela
0d63fcec-2881-4115-8a10-ff0f1033fe3c
Osborne, Wendy L.
c8ba0fc6-58eb-4ce3-ab6a-cf97b9beae01
Linton, Kim
e0291ae0-f9be-4a0d-81ef-949d46f9a661
Medd, Patrick G.
d84d8016-e33b-491c-9d20-490532ee72f0
Lown, Robert
74f3fa03-c54a-4fda-8989-34524b75b201
Davies, Andrew J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Al-Shamkhani, Aymen
0a40b3ce-9d71-4d41-9369-7212f0a84504
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Collins, Graham P.
383f579f-8748-4d35-9b60-74508fdcda90
Keler, Tibor
38add6e3-58be-4bc4-a9df-ba10c9e1ae1e
Yellin, Michael J.
cbfdf268-6282-4eeb-85d4-f709bfcfad43
Gentles, Andrew James
54d57537-0f70-4c9f-a8b1-166fa30c9434
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Lim, Sean H.
1afe5aa1-61a4-4a7b-927f-5e671f885196
et al.
Buermann, Lara E.
953ffde8-80f4-4bc7-b36b-0502d1e3ff82
Stanton, Louise
8b827763-d839-4b4b-bbf2-358a84110294
Rose-Zerilli, Matthew J.J.
08b3afa4-dbc2-4c0d-a852-2a9f33431199
Thorne, Kerensa
21a60886-12d9-4ace-b9cd-cf0f64aca53d
Coleman, Adam
49cf504d-6f2b-422b-9c3a-17eb5d5d6a85
Turaj, Anna H.
fbbc48ea-28cf-4db7-ae4a-c16ce7b3857a
Caddy, Joshua
c9f48059-2d70-45e4-a80a-978bf74fac34
Wignall, Christopher
0fd9e11b-8f96-467f-810c-041bbfca40bc
Keyworth, Nicole
3040ee74-31cf-4cbd-91ef-3223367f7253
Konn, Zoe
525b4648-7c88-488a-aefa-0018ac485eb4
McKay, Pamela
0d63fcec-2881-4115-8a10-ff0f1033fe3c
Osborne, Wendy L.
c8ba0fc6-58eb-4ce3-ab6a-cf97b9beae01
Linton, Kim
e0291ae0-f9be-4a0d-81ef-949d46f9a661
Medd, Patrick G.
d84d8016-e33b-491c-9d20-490532ee72f0
Lown, Robert
74f3fa03-c54a-4fda-8989-34524b75b201
Davies, Andrew J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Al-Shamkhani, Aymen
0a40b3ce-9d71-4d41-9369-7212f0a84504
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Collins, Graham P.
383f579f-8748-4d35-9b60-74508fdcda90
Keler, Tibor
38add6e3-58be-4bc4-a9df-ba10c9e1ae1e
Yellin, Michael J.
cbfdf268-6282-4eeb-85d4-f709bfcfad43
Gentles, Andrew James
54d57537-0f70-4c9f-a8b1-166fa30c9434
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Lim, Sean H.
1afe5aa1-61a4-4a7b-927f-5e671f885196

Buermann, Lara E., Stanton, Louise and Rose-Zerilli, Matthew J.J. , et al. (2025) CD27 agonist antibodies mediate clinical responses through intratumoral stimulation in B-cell malignancies: multicenter RiVa trial. Clinical Cancer Research. (doi:10.1158/1078-0432.CCR-25-2029).

Record type: Article

Abstract

Purpose: varlilumab is a CD27 agonist antibody, delivering a T-cell costimulation. Preclinical studies show that agonistic CD27 antibodies can activate intratumoral T-cells to release chemokines and cytokines to augment macrophage-dependent tumor killing induced by CD20 antibodies, i.e. rituximab, in B-cell lymphoma. This clinical trial evaluated the safety and efficacy of rituximab and varlilumab in patients with previously treated B-cell non-Hodgkin lymphoma (B-NHL).

Patient and methods: this multicenter phase IIa trial recruited patients with relapsed or refractory CD20+ B-NHL. Patients were randomized to Arm A or B. All received rituximab on Day 1 of Cycles1-6, and varlilumab on Day 2 (Arm A) or Day 8 (Arm B) of Cycle 1, and Day 2 of Cycles 3 and 5. Tumor biopsies were collecting pre-treatment and on-treatment (after varlilumab in Arm A and before varlilumab in Arm B). The primary objective was to assess safety and anti-tumor activity.

Results: twenty-seven participants were evaluable, with modest overall response and disease control rates of 15.4% (4/27) and 38.8% (8/27), respectively. Intratumoral bulk RNA sequencing analysis demonstrated that adding varlilumab to rituximab enhanced CD4+ T-cell infiltration and increased T- and innate-cell signatures; inflamed tumor signatures were observed pre-treatment in responders. Single-cell analysis further showed that higher levels of CD27-expressing T and NK cells, along with activated γδ T-cell signatures, were associated with response, whereas CD27-expressing B cells correlated with non-response.

Conclusions: rituximab and varlilumab show modest activity. However, CD27 agonist antibodies may elicit meaningful anti-tumor responses when tumors express sufficient intratumoral targets and exhibit existing immune priming.

Text
Buermann_et_al_CCR_proof_2025 - Accepted Manuscript
Restricted to Repository staff only until 10 October 2026.
Request a copy
Image
Figure1_panel_label_revised
Restricted to Repository staff only
Request a copy
Image
Figure2_panel_label_revised
Restricted to Repository staff only
Request a copy
Image
Figure3_panel_label_revised
Restricted to Repository staff only
Request a copy
Image
Figure4_panel_label_revised
Restricted to Repository staff only
Request a copy
Text
Supplemental_full
Restricted to Repository staff only
Request a copy

Show all 6 downloads.

More information

Accepted/In Press date: 2 September 2025
e-pub ahead of print date: 10 October 2025

Identifiers

Local EPrints ID: 506158
URI: http://eprints.soton.ac.uk/id/eprint/506158
ISSN: 1078-0432
PURE UUID: a84397db-9e76-4137-9c60-ec21a15b6a40
ORCID for Lara E. Buermann: ORCID iD orcid.org/0000-0002-7989-9404
ORCID for Louise Stanton: ORCID iD orcid.org/0000-0001-8181-840X
ORCID for Matthew J.J. Rose-Zerilli: ORCID iD orcid.org/0000-0002-1064-5350
ORCID for Anna H. Turaj: ORCID iD orcid.org/0000-0002-2664-8417
ORCID for Joshua Caddy: ORCID iD orcid.org/0009-0002-8434-4443
ORCID for Andrew J. Davies: ORCID iD orcid.org/0000-0002-7517-6938
ORCID for Peter W.M. Johnson: ORCID iD orcid.org/0000-0003-2306-4974
ORCID for Aymen Al-Shamkhani: ORCID iD orcid.org/0000-0003-0727-4189
ORCID for Mark S. Cragg: ORCID iD orcid.org/0000-0003-2077-089X
ORCID for Gareth Griffiths: ORCID iD orcid.org/0000-0002-9579-8021
ORCID for Sean H. Lim: ORCID iD orcid.org/0000-0002-2768-4858

Catalogue record

Date deposited: 29 Oct 2025 17:40
Last modified: 19 Nov 2025 02:48

Export record

Altmetrics

Contributors

Author: Lara E. Buermann ORCID iD
Author: Louise Stanton ORCID iD
Author: Kerensa Thorne
Author: Adam Coleman
Author: Anna H. Turaj ORCID iD
Author: Joshua Caddy ORCID iD
Author: Christopher Wignall
Author: Nicole Keyworth
Author: Zoe Konn
Author: Pamela McKay
Author: Wendy L. Osborne
Author: Kim Linton
Author: Patrick G. Medd
Author: Robert Lown
Author: Mark S. Cragg ORCID iD
Author: Graham P. Collins
Author: Tibor Keler
Author: Michael J. Yellin
Author: Andrew James Gentles
Author: Sean H. Lim ORCID iD
Corporate Author: et al.

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×